Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2024 | Second-line fulvestrant in pretreated metastatic invasive lobular carcinoma

Jason Mouabbi • 22 May 2024
ESMO Breast 2024
Breast Cancer Fulvestrant

Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the efficacy of second-line fulvestrant in patients with metastatic invasive lobular carcinoma (mILC) following treatment with aromatase inhibitors (AI) and CDK4/6 inhibitors, based on an observational study. Fulvestrant was found to be ineffective, and no patients assessed continued on fulvestrant after a year. These findings highlight the need for new therapeutic strategies in pre-treated mILC. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Jason Mouabbi

ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more
1:40
ASCO 2025 highlights in breast cancer: ASCENT-04, SERENA-6, and more
Jason Mouabbi • 31 May 2025
Fostering partnerships between clinicians & patient advocates in breast cancer
1:32
Fostering partnerships between clinicians & patient advocates in breast cancer
Jason Mouabbi • 31 May 2025
How will neoadjuvant endocrine therapy improve outcomes in ILC?
0:28
How will neoadjuvant endocrine therapy improve outcomes in ILC?
Jason Mouabbi • 31 May 2025
Comparing NAET versus NAC in stage II/III ER+/HER2- invasive lobular carcinoma
0:59
Comparing NAET versus NAC in stage II/III ER+/HER2- invasive lobular carcinoma
Jason Mouabbi • 31 May 2025

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026
The content of VJOncology is intended for healthcare professionals